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Aim. To explore the potential of transrectal magnetic resonance image- (MRI-) guided biopsies of the prostate in a patient cohort
with prior negative ultrasound guided biopsies. Patients and Methods. Ninety-six men with suspected prostate cancer underwent
MRI-guided prostate biopsies under real-time imaging control in supine position. Results. Adenocarcinoma of the prostate was
detected in 39 of 96 patients. For individual core biopsies, MRI yielded a sensitivity of 93.0% and a speciﬁcity of 94.4%. When
stratifying patients according to the free-to-total prostate-speciﬁc antigen (PSA) ratio, the prostate cancer discovery rate was
signiﬁcantly higher in the group with ratios less than 0.15 (57.1%). Conclusion. MRI-guided biopsy of the prostate is a diagnostic
option for patients with suspected prostate cancer and a history of repeatedly negative transrectal ultrasound-guided biopsies.
Combined with the free-to-total PSA ratio, it is a highly eﬀective method for detecting prostate cancer.
1.Introduction
Digital rectal examination, transrectal ultrasound (TRUS),
serum PSA assay, and TRUS-guided prostate biopsy are
common methods used for prostate cancer evaluation. In
addition, the feasibility of MR imaging, MRSI, and DCE-
MRI in the diagnostic process of prostate cancer have
been reported in several studies [1, 2]. MRI is capable
of displaying the prostate in the T2-weighted image with
its zonal anatomy and tumor-suspected areas within the
high signal peripheral zone. The reported sensitivity for the
detection of prostate cancer by MRI varies between 57%
and 100% and the speciﬁcity between 44% and 96% for
predicting positive biopsies [3]. Although the results diﬀer
somewhat, endorectal MRI seems to oﬀer notably higher
sensitivity compared to TRUS for the detection of prostate
cancer. Consequently, there is increasing interest in using
this MRI method for prostate cancer diagnosis in patients
with suspected prostate cancer and prior tumor-negative
TRUS-guided prostate biopsies. In 2000, endorectal MRI-
guided biopsy of the prostate was ﬁrst described as a
transperineal puncture in one man [4]. In the meantime,
other studies have been published, yet most of them report
on only small numbers of patients [5, 6]. One early
study comprised 12 patients, who had received MRI-guided
prostate biopsy in a prone position [7]. In 2010, Hambrock
reported results from the largest series, until now, with
68 patients using a 3 Tesla Trio Tim MR scanner [8]. In
the present study, we report our results from endorectal
MRI-guided prostate biopsies in 96 patients, which were
performed in a supine position.
2. Patients andMethods
2.1. Study Population and Histological Evaluation. After
approval from the local ethical committee, a total of 96 men
underwent endorectal MRI-guided prostate biopsy between2 The Scientiﬁc World Journal
(a) (b) (c)
Figure 1: Prostate biopsy in a 1.5-T MRI system. (a) MR-image of a prostate gland with tumor-suspected area. (b) Prostate gland with
needle guidance being positioned towards the tumor-suspected area. (c) Biopsy needle in the tumor-suspected area. In every image, the
t u m o r - s u s p e c t e da r e ai sm a r k e db ya na r r o w .
December, 2003 and December, 2007. Informed consent was
retrieved from every participant. All of these patients had
previously undergone TRUS-guided prostate biopsies (1 to
6 sessions) with tumor-negative results and a continuing
clinical suspicion of prostate cancer. Patients were excluded
if they had any of the usual contraindications to MRI (e.g.,
cardiac pacemakers or other metallic implants). No further
patient selection was applied. Histological examination of
the core biopsies was performed by experienced patholo-
gists using hematoxylin-eosin staining on formalin-ﬁxed,
paraﬃn-embedded sections. Immunohistochemical studies,
using the basal cell marker p63 and P504S/alpha-methylacyl-
coenzyme Aracemase,wereperformedincasesthat werenot
clearly cancerous based on morphology alone.
2.2. MRI and Prostate Biopsy Technique. All patients under-
went diagnostic MRI with an endorectal body phased-array
coil before undergoing MRI-guided biopsy in a 1.0 Tesla
(T) (n = 31) or 1.5T (n = 66) MRI scanner under real-
time MR-imaging control. The criteria used for malignancy
in MRI were reported recently by Engelhard et al. [5].
We analyzed T2-weighted images to identify profoundly
suspect or moderately suspect target regions. However, T2-
weighted imaging has signiﬁcant limitations for depicting
cancer, especially in the transitional and central zone as
well as in the anterior part of the peripheral zone, because
cancer and normal tissues both have low signal intensity on
T2-weighted images in these areas. In addition, low signal
intensity may be seen in the peripheral zone on T2-weighted
images in the presence of many noncancerous abnormal
conditions,suchasnonspeciﬁcinﬂammation,biopsy-related
hemorrhage, postradiation ﬁbrosis, and changes following
hormone deprivation therapy [9, 10]. Therefore, we deﬁned
profoundly tumor-suspect regions within the normally high
signal peripheral zone as asymmetric hypointense lesions.
In the front gland (transitional zone and central zone)
moderately tumor-suspect regions were deﬁned as low signal
intensity lesions depending on the circumjacent tissue when
they were enclosed by structures with higher signal within
the scope of an adenomatous hyperplasia [5].
Prostate biopsy was performed with the patients posi-
tioned in a supine position within a closed 1.0- or 1.5-
T MRI system (MAGNETOM Symphony, Siemens Medical
Solutions, Erlangen, Germany) as already described [5].
A prophylactic antibiotic therapy was given (Ciproﬂoxacin
250mg 1-0-1/d) for 5 days, starting 2 days before the proce-
dure.Nopatientreceivedgeneralanesthesiaorsedation,only
mucosal inﬁltration analgesia of the rectum was adminis-
tered (Mepivacainhydrochlorid 1%, 2mL). After localization
of the tumor-suspected area, the MR-visible biopsy needle
guide was inserted into the patient’s rectum and guided to
the area to be punctured, as shown in Figure 1. The biopsies
were performed using an MR-compatible biopsy gun (fully
automatic BiopsyGun—16 G, INVIVO Germany, Schwerin,
Germany). The correct position of the biopsy needle in
the target area was documented. Two-to-six biopsy cores
from each patient were extracted with at least one from
the suspected area and at least one negative control biopsy.
These negative control biopsies were extracted from areas
without tumor-suspicious lesions, preferably contralateral to
the major suspicious area. The MRI intervention took 40 to
60 minutes per patient.
2.3. Statistical Analysis. The median and range were used
to describe the data, and nonparametric test statistics
were applied. Prevalence, sensitivity, and speciﬁcity were
calculated by 4 ﬁeld charts. Fisher’s exact test was used
for comparison of prostate cancer detection rates between
the group with free-to-total PSA ratios <0.15 and the
group with ratios ≥0.15. Population characteristics between
patients with or without prostate cancer were compared
using Mann-Whitney U-test statistics. The ability of the
free-to-total PSA ratio to discriminate between patients
with or without prostate cancer was analyzed using receiver
operating characteristics. The cutoﬀ value with the best
overall performance was selected according to the respective
likelihood ratio. Statistical signiﬁcance was considered atThe Scientiﬁc World Journal 3
Table 1: Patients’ characteristics.
Median (range) Median
Variable All patients (n = 96) Prostate cancer detected (n = 39) No prostate cancer detected (n = 57) P valuea
Age (years) 66.2 (45.6–84) 67.3 65.9 0.69
Total serum PSA (ng/mL) 9.4 (1.0–48.8) 11.2 8.5 0.0039
Free serum PSA (ng/mL)b 1.2 (0.1–5.6) 1.3 1.1 0.78
Free/Total PSA ratiob 0.1 (0.04–0.5) 0.1 0.2 0.005
Prostate volume (mL) 37 (12–120) 34 40 0.081
aP values of variables with or without prostate cancer detection were compared using Mann-Whitney U-test statistics.
bFree PSA measurements were available from 69 patients.
Table 2: Sensitivity and speciﬁcity.
Pathological report
MRI-guided bopisy Tumor Normal
Malignancy suspected 69 3
Malignancy not suspected 3 63
In a cohort of 31 patients with histological conﬁrmed prostate cancer, a total of 138 biopsy cores were extracted.
P values ≤0.05. Statistical analyses were performed using
Prism 4.0 software (GraphPad Inc, La Jolla, Calif, USA). A
core biopsy taken from an area suspected for malignancy by
MRI was considered to be true-positive when the imaging
results were conﬁrmed by histology. Likewise, core biopsies
taken from areas not suspected by MRI were considered to
be true negative when histology did not show malignancy.
3. Results
A total of 96 men underwent MRI-guided prostate biopsy
in the supine position. Table 1 lists the patient demographic
andtumorcharacteristics.TherewasinformationonthePSA
isoforms for 69 patients, with free PSA ranging from 0.12 to
5.64ng/mL (median 1.24ng/mL) and the free-to-total PSA
ratio ranging from 0.04 to 0.5 (median 0.14).
3.1. Analysis of MRI-Guided Core Biopsies. During MRI
intervention, an average of 4.3 biopsy cores (range 2 to 6)
were extracted per patient (Figure 1). Prostate cancer was
histologically conﬁrmed in 39 of the 96 patients, corre-
sponding to a detection rate of 40.6%. Patients with tumor-
negative histology results were transferred to a continuous
surveillance scheme with a median follow-up time of 1.7
years (range: 2 months–4.5 years). In ten of these 57 patients,
prostate cancer was detected within an interval of three
years after MRI intervention. Of these, prostate cancer
was identiﬁed by TRUS-guided saturation biopsy in two
patients and by transurethral resection of the prostate due
to bladder outlet obstruction in eight patients. Assuming
these interval carcinomas were already present at the time of
MRI intervention, the rate of missed cancers by MRI-guided
prostate biopsy in our series was at most 10.4%.
Thirty-one of the patients with conﬁrmed prostate can-
cer underwent radical prostatectomy in our institution. After
review of the prostatectomy specimens by an experienced
pathologist, we estimated the accuracy of MRI-guided core
biopsies in detecting prostate cancer. In our patient cohort
with histological conﬁrmed prostate cancer, 138 biopsy cores
were extracted, 72 from areas suspected of malignancy
according to the above-mentioned MRI criteria, and 66
from areas that appeared normal. Malignancy was correctly
observed in 69 biopsies, while three false-positive, 63 true-
negative, and three false-negative results were observed
(Table 2). These results yielded a sensitivity of 95.8% and a
speciﬁcity of 95.5%, with a positive predictive value of 95.8%
and a negative predictive value of 99.5% to 95.5%.
Next, we compared whether the location of areas sus-
pected of malignancy matched those listed in the patholo-
gist’s ﬁnal report. In the majority of cases, the location of
prostate cancer was correctly determined by MR imaging.
Onlyin12casesthepathologist’sﬁnalreportrevealedamore
widespread cancer than determined by MRI.
The free-to-total PSA ratio was a strong predictor of
prostate cancer detection by MRI-guided prostate biopsy.
To determine the cutoﬀ value of the free-to-total PSA ratio,
the speciﬁcity and sensitivity for prostate cancer detection
were calculated on the basis of the receiver operating
characteristics (ROC) curve (area under the curve 0.70, 95%
CI, 0.57–0.83, P = 0.0054; Figure 2). Applying this cutoﬀ
value, there was a highly signiﬁcant diﬀerence in the cancer
detection rate using MRI-guided prostate biopsy between
m a l e sw i t haP S Ar a t i o<0.15 compared to those with a
PSA ratio ≥0.15 (P = 0.0073, Fisher’s exact test). In 35
patients with a ratio <0.15, the prostate cancer detection
rate was 57.1% (20 of 35), while in 33 patients with a ratio
≥0.15, prostate cancer was detected in only eight patients
(24.2%; Table 3). Of the 10 patients with negative MRI-
guided prostate biopsies, who revealed prostate cancer after
MRI intervention, seven patients showed a free-to-total PSA
ratio <0.15 (70%).
3.2. Clinical Complications. Twenty-three patients developed
gross hematuria for less than six hours. Sixteen patients4 The Scientiﬁc World Journal
Table 3: Relationship of free/total PSA ratio and prostate cancer detection by MRI-guided biopsy.
Free/total PSA ratio Prostate cancer detected (%)
≥0.15 (n = 33) 8 (24.2)
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Figure 2: ROC curve for the cutoﬀ value of the free-to-total PSA
ratio, the speciﬁcity, and sensitivity for prostate cancer detection
with the MRI-guided biopsy technique. The horizontal and vertical
lines mark the sensitivity and speciﬁcity at the selected cutoﬀ of
0.15.
reported short-term perianal bleeding. Urinary retention
requiringasinglecatheterizationoccurredinonepatient.No
patients were hospitalized for complications.
4. Discussion
Today, TRUS-guided prostate biopsy is the gold standard
for the diagnosis of prostate cancer. When applied as a
sextant biopsy in patients with a total PSA value ranging
from 4–10ng/mL, this approach yields a sensitivity of 39%–
52% and a speciﬁcity of 81%-82% [11]. Yet, about 20% of
prostate cancers are not detected at the ﬁrst biopsy. If the
ﬁrstbiopsyisnegative,arepeatbiopsymayberecommended,
which has a cancer detection rate between 20% to 35% [12–
15]. De la Taille has reported even higher cancer detection
rates with extended biopsy schemes (more than 12 cores
up to saturation biopsy schemes ≥20 cores) [16]. A meta-
analysis studied the eﬃcacy and adverse eﬀects of various
biopsy schemes and found that an extended biopsy with 12
cores strikes a balance between adequate cancer detection
and an acceptable level of adverse eﬀects. However, biopsies
of more than 12 cores seemed to be of no signiﬁcant
beneﬁt in cancer detection, and biopsies with 18 or more
cores had a poor side-eﬀect proﬁle [17]. Targeted biopsies,
directed by contrast enhanced doppler ultrasound, showed
detection rates similar to those seen with systematic biopsies;
nevertheless, this technique has not yet gained widespread
acceptance not even in the repeat biopsy setting [18–20].
Onestudyonrepeatbiopsiesanalyzedthevalueofsaturation
prostate biopsies, where 41 to 76 cores were taken per
patient.Inaccordancewithotherstudies,theyreportedalow
diagnostic yield with a cancer detection rate of 11%, which is
comparable to traditional biopsy schemes [21].
Due to dramatic improvements in MR imaging, this
technology has gained growing importance in the diagnosis
of prostate cancer. The capability of combining MR imaging
with techniques to simultaneously perform a targeted biopsy
of the prostate is of particular interest to urologists. The ﬁrst
report on MRI-guided biopsy of the prostate was published
in 2000 describing a transperineal puncture in one patient
in the lithotomy position under general anesthesia [4]. Soon,
other reports described transrectal punctures with patients
placed in a prone position [5, 7].
In our study cohort, consisting of 96 patients with one
or more previous negative TRUS-guided biopsy sessions,
prostate cancer was detected in 40.6% of the cases using
MRI-guided targeted biopsy. This high rate of prostate
cancer detection not only demonstrates the feasibility of MR
imaging in combination with simultaneous prostate biopsy,
but also the excellent performance of MR imaging in this
diﬃcult to treat patient cohort. For individual core biopsies,
our technique yields a sensitivity of 95.8%, a speciﬁcity of
95.5%, a positive predictive value of 95.8%, and a negative
predictive value of 95.5%. An even higher detection rate
could be achieved when patients were stratiﬁed according
to their free-to-total PSA ratio. The group with a PSA ratio
<0.15 had a detection rate of 57.1% versus 24.2% for the
g r o u pw i t haP S Ar a t i o≥0.15.
It is diﬃcult to estimate the rate that the presence of
prostate cancer was not detected. Yet, we determined a rough
estimation from our follow-up evaluations of 57 men with
negativeMRI-guidedbiopsies.In10patients,prostatecancer
was diagnosed within 3 years after the MRI intervention.
Assuming these interval carcinomas were already present at
thetimeofMRIintervention, theratethatcancerwasmissed
is at most 10.4%. Following an initial negative saturation
biopsy, a notably higher rate (24%) of subsequent prostate
cancer detection during followup has been reported [22]. It
isofparticularnotethatinourseries,sevenofthe10patients
with an interval prostate cancer had a free-to-total PSA ratio
<0.15 at the time of MRI intervention, further emphasizing
the PSA ratio is an important predictor of prostate cancer.
The complications associated with MRI-guided prostate
biopsy in our study, such as hematuria, perianal bleeding,
or urinary retention, are comparable to those associated
with TRUS-guided biopsies [23, 24], and their rates are
similar to those reported in recent studies on MRI-guided
biopsytechniques[6,7,25].Majorcomplicationswarranting
hospitalization were not observed. This is in contrast to
complications arising after saturation prostate biopsies,
which include sepsis and occur at a rate of 12% [26].The Scientiﬁc World Journal 5
Although MRI-guided prostate biopsy is time consum-
ing, it can be recommended for patients with persisting
prostate cancer suspicion despite a prior negative TRUS-
guided biopsy. In our series of patients with prior negative
prostate biopsies, we observed an improved prostate cancer
detection rate of over 40% in MRI-guided prostate biopsy
compared to 20% to 35% reported for conventional TRUS-
guided repeat biopsies.
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